HHS and FDA Clinical Trials Reform: "Operation Trailblazer" and the Proposed Expedited-IND Pilot Program
On June 22, 2026, the U.S. Department of Health and Human Services (HHS), led by Secretary Robert F. Kennedy, Jr., and the FDA formally launched "Operation Trailblazer", a department-wide initiative designed to sweepingly reform U.S. clinical trials and counter the growing dominance of China in early-stage clinical research. As the first major operational step under this initiative, the FDA published a Request for Information (RFI) in the Federal Register on June 24, 2026, proposing the establishment of an Expedited-IND Pilot Program.
The proposed pilot program aims to reduce the start-up time for first-in-human (FIH) Phase 1 clinical trials in the United States by 6 to 12 months, and potentially cut overall clinical trial timelines in half.1 The core mechanism of the proposal is the creation of a network of "Qualified Research Institutions" (QRIs)—American academic medical centers and research hubs that would pre-screen Investigational New Drug (IND) components (including pharmacology/toxicology, clinical, and CMC data) and make rolling recommendations to sponsors and the FDA to preemptively resolve issues that lead to clinical holds.
The initiative is a direct response to geopolitical competition. China surpassed the U.S. in its global share of Phase 1 clinical trials in 2021 and has continued to widen its lead by streamlining its regulatory pathways and investing heavily in clinical infrastructure.
According to legal and policy analysis by Arnold & Porter:
"FDA’s proposed Expedited-IND Pilot program is aimed at reversing a trend of clinical research and development moving abroad, namely to China.234 China surpassed the U.S. for the global share of phase 1 clinical trials in 2021 and has continued to extend its lead in the number of early-stage trials globally. Operation TrialBlazer recognizes that China is gaining this competitive advantage since streamlining its regulatory pathways5 and strengthening its clinical trial infrastructure, which attract sponsors and investment for conducting clinical trial research."
Under the proposed structure, QRIs will act as advisory bodies to improve IND submission quality, while the FDA retains full regulatory oversight, including the final "safe to proceed" authority. The public comment period for the RFI is open through July 22, 2026.
-
An instance of Domestic pharmaceutical initiatives serve as trade shield programs to counter foreign supply chains. — The US is launching fast-track regulatory pilots to shorten trial timelines to prevent clinical trials from migrating to overseas competitors. ↩︎
-
An instance of Geopolitical competition drives the wholesale acceleration of early-stage trials. — This line highlights how intense geopolitical competition from China is driving the U.S. executive to aggressively accelerate and streamline domestic early-stage clinical trial approvals. ↩︎
-
An instance of Legacy regulatory bottlenecks collapse when strategic global competition and supply deficits demand rapid market entry. — It highlights how geopolitical competition drives regulators to overhaul clinical entry points to prevent losing domestic R&D dominance. ↩︎
-
An instance of Federal manufacturing fast-tracks shield critical clinical supply chains from geopolitical reliance. — This pilot program establishes a pre-clearance research network specifically to prevent early-stage clinical pipelines from migrating to geopolitical rivals. ↩︎
-
An instance of Geopolitical rivalry forces sovereign regulators to overhaul early-stage clinical trial trial structures. — In response to losing dominant global market share to China, the FDA launched an expedited pilot program to cut early trial timelines. ↩︎